Human prostate cancer risk factors (Q34360616)

1 August 2017

1 reference

title

Human prostate cancer risk factors (English)

1 reference

1 August 2017

1 reference

David G Bostwick

1

1 reference

1 August 2017

Harry B Burke

2

1 reference

1 August 2017

Daniel Djakiew

3

1 reference

1 August 2017

Susan Euling

4

1 reference

1 August 2017

Shuk-mei Ho

5

1 reference

1 August 2017

Joseph Landolph

6

1 reference

1 August 2017

Howard Morrison

7

1 reference

1 August 2017

Babasaheb Sonawane

8

1 reference

1 August 2017

Tiffany Shifflett

9

1 reference

1 August 2017

David J Waters

10

1 reference

1 August 2017

Barry Timms

11

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

1 August 2017

1 reference

1 August 2017

101

1 reference

1 August 2017

2371-2490

1 reference

1 August 2017

10 Suppl

1 reference

Crystalloids in metastatic prostatic adenocarcinoma

1 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Risk factors for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Serum testosterone and dihydrotestosterone in carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Endogenous mutagens and the causes of aging and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Metallothionein protects DNA from oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Homocysteine, oxidative stress, and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Factor analysis of international cancer mortality data and per capita food consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Nutrition, social factors and prostatic cancer in a Northern Italian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Serum retinol and subsequent risk of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

A case-control study of cancer of the prostate in Somerset and east Devon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Vasectomy, cigarette smoking, and age at first sexual intercourse as risk factors for prostate cancer in middle-aged men

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Latent effects of pesticides and toxic substances on sexual differentiation of rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

A review of the carcinogenicity of chemicals most frequently found at National Priorities List sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

A cohort study of mortality from cancer of the prostate in Catholic priests

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Tissue-specific and hormonal regulation of the gene for rat prostatic steroid-binding protein in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Stereologically estimated mean nuclear volume of prostatic cancer is a reliable prognostic parameter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Morphonuclear relationship between prostatic intraepithelial neoplasia and cancers as assessed by digital cell image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Cellular adhesion molecules in urologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Benign Prostatic Hyperplasia: Pathogenesis and Medical Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Growth of methionine-dependent human prostate cancer (PC-3) is inhibited by ethionine combined with methionine starvation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

Detection by DNA fingerprinting of somatic changes during the establishment of a new prostate cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

21 January 2018

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Developmental stage sensitivity and mode of action information for androgen agonists and antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epidemiologic evidence regarding predisposing factors to prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cancer statistics, 1993

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epidemiology of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cancer incidence and mortality, 1973-1995: a report card for the U.S.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Recent cancer trends in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Changing trends in U.S. prostate cancer incidence rates.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate carcinoma incidence and patient mortality: the effects of screening and early detection.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

An adjustment to the 1997 estimate for new prostate cancer cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Rise in prostatic cancer incidence associated with increased use of transurethral resection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cancer of the prostate: epidemiology and aetiology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Age and racial distribution of prostatic intraepithelial neoplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate cancer screening (United States).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The epidemiology of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The association of benign prostatic hyperplasia and cancer of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Genetic susceptibility of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Concordance rates for benign prostatic disease among twins suggest hereditary influence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic intraepithelial neoplasia: the preinvasive stage of prostate cancer. Overview of the prostate committee report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Intraductal dysplasia: a premalignant lesion of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic intra-epithelial neoplasia and early invasion in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Precursors of prostatic cancer: progression, regression and chemoprevention

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prevalence of prostatic intra-epithelial neoplasia (PIN) in biopsies from hospital practice and pilot screening: clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Transurethral biopsy of the prostate for persistently elevated or increasing prostate specific antigen following multiple negative transrectal biopsies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen deprivation as a strategy for prostate cancer chemoprevention.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mucin expression in atypical adenomatous hyperplasia of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Sulfur-rich prostatic intraluminal crystalloids: a surgical pathologic and electron probe x-ray microanalytic study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prevalence and Location of Peripheral Nerve Found on Prostate Needle Biopsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Correlation of perineural invasion on radical prostatectomy specimens with other pathologic prognostic factors and PSA failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperativ

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Incidence and prognostic significance of lymphatic and vascular invasion in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic intra-epithelial neoplasia: expression and location of proliferating cell nuclear antigen in epithelial, endothelial and stromal nuclei

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Topography of neovascularity in human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Biological determinants of cancer progression in men with prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Microvascular Invasion in Prostate Cancer: Prognostic Significance in Patients Treated by Radical Prostatectomy for Clinically Localized Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Family history and the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Familial patterns of prostate cancer: a case-control analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Family history and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Does a family history of prostate cancer result in more aggressive disease?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Familial study of prostate cancer in Jamaica

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Familial prostate cancer and possible associated malignancies: nation-wide register cohort study in Sweden

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Hereditary prostate cancer and other genetic predispositions to prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Genetic predisposition to prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate cancer risk. Medical history, sexual, and hormonal factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Family history and the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Role of family history and ethnicity on the mode and age of prostate cancer presentation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A systematic review and meta-analysis of familial prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Family aggregation of cancer of the prostate in Quebec: the tip of the iceberg

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epidemiology of prostatic cancer: a case-control study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Studies of genetic factors in prostate cancer in a twin population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Risk of prostate cancer associated with a family history in an era of rapid increase in prostate cancer diagnosis (Australia)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Concerning a familial association between breast cancer and both prostatic and uterine malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Breast Cancer Risks in Relatives of Male Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vitamin D receptor genotype and the risk of bone fractures in women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Association between breast cancer and family malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Parental age at child's birth and son's risk of prostate cancer. The Framingham Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate Cancer: A Current Perspective

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Reduced circulating androgen bioactivity in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Familial factors affecting prostatic cancer risk and plasma sex-steroid levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Design of the Prostate Cancer Prevention Trial (PCPT).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Diabetes mellitus and risk of prostate cancer (United States).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Endogenous sex hormone levels in older adult men with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Plasma prolactin and prostate cancer risk: A prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Leptin and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Leptin influences cellular differentiation and progression in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

International trends and patterns of prostate cancer incidence and mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epidemiology of prostate cancer: molecular and environmental clues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cancer mortality in Chinese immigrants to New York City. Comparison with Chinese in Tianjin and with United States-born whites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epidemiology of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Explaining the difference in prostate cancer mortality rates between white and black men in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Links between genetic and environmental factors and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Intake of carotenoids and retinol in relation to risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Theories of biological aging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Superoxide dismutase, aging, and degenerative disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effects of peroxidative stress and age on the concentration of a deoxyguanosine-malondialdehyde adduct in rat DNA

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dietary butylated hydroxytoluene counteracts with paraquat to reduce the rate of hepatic DNA single strand breaks in senescence-accelerated mice.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Oxidative stress, caloric restriction, and aging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Protein oxidation and aging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Diet, androgens, oxidative stress and prostate cancer susceptibility

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Production and repair of DNA damage in mammalian cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.20408

1 reference

7 January 2021

Increase in metallothionein produced by chemicals that induce oxidative stress

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of several metallothionein inducers on oxidative stress defense mechanisms in rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Oxidative stress in mitochondria: its relationship to cellular Ca2+ homeostasis, cell death, proliferation, and differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tissue injury by free radicals.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Influence of vitamins A, C, and E and beta-carotene on aflatoxin B1 binding to DNA in woodchuck hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

DNA base modifications and antioxidant enzyme activities in human benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Infrared spectral models demonstrate that exposure to environmental chemicals leads to new forms of DNA.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prooxidant states and tumor promotion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Quantity and saturation degree of dietary fats as modulators of oxidative stress and chemically-induced liver tumours in rats.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mechanisms of fat-related modulation of N-nitrosodiethylamine-induced tumors in rats: organ distribution, blood lipids, enzymes and pro-oxidant state

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Physical activity and prostate cancer in the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study (Finland).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate Cancer and Supplementation With α-Tocopherol and β-Carotene: Incidence and Mortality in a Controlled Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Carotenoid content of fruits and vegetables: an evaluation of analytic data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Sex hormone-induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Induction of a DNA adduct detectable by 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17 beta and testosterone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nutrition and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Association of energy and fat intake with prostate carcinoma risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nutrition and prostate cancer: a case-control study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Diet and prostatic cancer: a case-control study in Hawaii

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Beta-carotene and animal fats and their relationship to prostate cancer risk. A case-control study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Diet and prostatic cancer: a case-control study in northern Italy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dietary factors and risk of prostate cancer: a case-control study in Ontario, Canada.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nutritional factors and prostate cancer: a case-control study of French Canadians in Montreal, Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Case-control study of diet and prostate cancer in China

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Diet and cancer of the prostate: a case-control study in Greece.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dietary fat intake and prostate cancer risk: a case-control study in Spain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A prospective study of dietary fat and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cohort study of diet, lifestyle, and prostate cancer in Adventist men.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Animal fat consumption and prostate cancer: a prospective study in Hawaii

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dietary fat intake and risk of prostate cancer: A prospective study of 25,708 Norwegian men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Fraction of prostate cancer incidence attributed to diet in Athens, Greece

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic levels of fatty acids and the histopathology of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prospective study of plasma fatty acids and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The role of diet in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The association of fatty acids with prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A prospective study on intake of animal products and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Foods, nutrients and prostate cancer: a case-control study in Uruguay

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Fatty fish consumption and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Signaling to a B-cell clone by Ek, but not Ak, does not reflect alteration of Ak genes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dietary fat and prostate cancer: current status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dietary vitamin A and cancer--a multisite case-control study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Serum retinol and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Serum selenium and subsequent risk of cancer among Finnish men and women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epidemiological study of prostatic cancer by matched-pair analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The dietary antioxidant network and prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability, and DNA synthesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate cancer: seventeen-year follow-up of the prospective basel study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vitamin D and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vitamin D and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effects of long-term alpha-tocopherol supplementation on serum hormones in older men.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Zinc, copper and selenium in reproduction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Zinc in the human prostate gland: normal, hyperplastic and cancerous

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibitory effect of zinc on human prostatic carcinoma cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Zinc and cadmium concentrations in whole tissue and in separated epithelium and stroma from human benign prostatic hypertrophic glands

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Zinc and cadmium plasma and erythrocyte levels in prostatic carcinoma, BPH, urological malignancies, and inflammations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Subcellular distribution of zinc in the benign and malignant human prostate: evidence for a direct zinc androgen interaction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Zinc potentiation of androgen receptor binding to nuclei in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Zinc, Vitamin A and Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Zinc plasma levels in prostatic carcinoma and BPH

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Ratio of post-prostatic massage urinary zinc concentration to initial urinary zinc concentration. An improved method of assessing prostatic function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Intracellular distribution of calcium and zinc in normal, hyperplastic, and neoplastic human prostate: X-ray microanalysis of freeze-dried cryosections

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Zinc supplement use and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Occupation, cadmium exposure, and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Selenium. Mechanistic aspects of anticarcinogenic action

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Serum retinol, beta-carotene, vitamin E, and selenium as related to subsequent cancer of specific sites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prediagnostic serum selenium and risk of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dairy products and the risk of prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Calcium, dairy products, and the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Growth of heterotopic LNCaP prostate cancer tumor in nude mice is not affected by dietary calcium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Medical, life-style, and occupational risk factors for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Alcoholism and cancer risk: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Smoking, alcohol, coffee, tea, caffeine, and theobromine: risk of prostate cancer in Utah (United States).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Alcohol and other beverage use and prostate cancer risk among Canadian men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Risk factors for prostate cancer: a case-control study in Greece

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tea and other beverage consumption and prostate cancer risk: a Canadian retrospective cohort study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Meta-analysis for combining relative risks of alcohol consumption and prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Case-control study of prostate cancer and socioeconomic factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Smoking and drinking habits in relation to prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Alcohol use and prostate cancer risk in US blacks and whites.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Alcohol and prostate cancer in the NHANES I epidemiologic follow-up study. First National Health and Nutrition Examination Survey of the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Case-control study of alcohol consumption and prostate cancer risk in Montréal, Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cigarette smoking and serum sex hormones in men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epidemiology of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cadmium and prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Associations of cancer site and type with occupation and industry from the Third National Cancer Survey Interview

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Doppler ultrasound of the prostate in normal dogs and in dogs with chronic lymphocytic-lymphoplasmocytic prostatitis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Case-control study of prostatic cancer in Kyoto, Japan: demographic and some lifestyle risk factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Smoking habits and prostate cancer: a case-control study in northern Italy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tobacco use and prostate cancer in blacks and whites in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Associations between Cigarette Smoking and Each of 21 Types of Cancer: A Multi-Site Case-Control Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cigarette smoking and prostate cancer: no relation with six measures of lifetime smoking habits in a large case-control study among U.S. whites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Joint effects of smoking and body mass index on prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Smoking and prostate cancer: Findings from an Australian case-control study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Smoking habits and risk of cancers other than lung cancer: 28 years' follow-up of 26,000 Norwegian men and women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cigarette smoking and risk of prostate cancer in the physicians' health study (United States)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Smoking and mortality: A prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mortality in relation to cigarette and pipe smoking: 16 years' observation of 25,000 Swedish men.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tobacco use and prostate cancer: 26-year follow-up of US veterans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Smoking and fatal prostate cancer in a large cohort of adult men.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mortality in relation to smoking: 40 years' observations on male British doctors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Impact of smoking on cancer stage at diagnosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Consensus conference: smoking and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Diabetes mellitus and the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vegetable and fruit consumption in relation to prostate cancer risk in Hawaii: a reevaluation of the effect of dietary beta-carotene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Fruit and vegetable intakes and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tomatoes, lycopene, and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A prospective study of tomato products, lycopene, and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Lycopene as the most efficient biological carotenoid singlet oxygen quencher

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Developmental effects of endocrine-disrupting chemicals in wildlife and humans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Naturally occurring oestrogens in foods--a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Geographic pathology of latent prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Phytoestrogen intake and prostate cancer: a case-control study using a new database

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Developmental estrogenization and prostatic neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Transport of steroids between fetuses via amniotic fluid in relation to the intrauterine position phenomenon in rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Intrauterine position effects on steroid metabolism and steroid receptors of reproductive organs in male mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cloning of a novel receptor expressed in rat prostate and ovary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Respiratory-cancer clustering associated with localised industrial air pollution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Role of cadmium in carcinogenesis with special reference to cancer of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Metal-androgen interrelationships in carcinoma and hyperplasia of the human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The mortality of cadmium workers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cadmium and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Percutaneous cryoablation of the prostate: preliminary results after 95 procedures

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression and regulation of metallothionein mRNA levels in the prostates of noble rats: lack of expression in the ventral prostate and regulation by sex hormones in the dorsolateral prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Carcinogenic effects of cadmium on the prostate of the rat

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Enhancing effect of cadmium on rat ventral prostate carcinogenesis induced by 3,2'-dimethyl-4-aminobiphenyl

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Oncogenicity of rat prostate cells transformed in vitro with cadmium chloride.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Selenium prevents the growth stimulatory effects of cadmium on human prostatic epithelium.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Zinc and cadmium concentration in prostatic carcinoma of different histological grading in comparison to normal prostate tissue and adenofibromyomatosis (BPH)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Work environment and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate cancer in pesticide applicators in Swedish agriculture

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prevalence of pesticide exposure in young males (≤ 50 years) with adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate cancer risk in California farm workers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Farming and prostate cancer mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate cancer and exposure to pesticides in agricultural settings

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Meta-analyses of prostate cancer and farming

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Physical activity and the risk of prostate and testicular cancer: a cohort study of 53,000 Norwegian men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cancer mortality pattern associated with exposure to metals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mortality among white and nonwhite farmers in North Carolina, 1976-1978.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mortality among rubber workers. I. White male union employees in Akron, Ohio

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mortality and cancer morbidity among workers in the rubber tire industry.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic cancer: relationship to suspended particulate air pollution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The etiology of prostate cancer: what does the epidemiology suggest?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Associations between several sites of cancer and nine organic dusts: results from an hypothesis-generating case-control study in Montreal, 1979-1983.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Metal workers and repairmen at risk for prostate cancer: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Case-control study of prostatic cancer in employees of the United Kingdom Atomic Energy Authority

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Association between diesel exposure at work and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Electromagnetic fields, polychlorinated biphenyls, and prostate cancer mortality in electric utility workers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate cancer risk and exposure to ultraviolet radiation: further support for the protective effect of sunlight.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Structural analysis of the C-CAM1 molecule for its tumor suppression function in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Meta-analysis of measures of sexual activity and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Sexual factors and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A prospective cohort study of vasectomy and prostate cancer in US men.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A retrospective cohort study of vasectomy and prostate cancer in US men.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vasectomy and the risk of prostatic cancer and benign prostatic hypertrophy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vasectomy and the risk of prostate cancer in a cohort of multiphasic health-checkup examinees: second report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Incidence of disease after vasectomy: a record linkage retrospective cohort study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Risk of testicular cancer after vasectomy: cohort study of over 73,000 men.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vasectomy and the risk of prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vasectomy and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vasectomy and prostate cancer: results from a multiethnic case-control study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vasectomy and prostate cancer in US blacks and whites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The relation of vasectomy to the risk of cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vasectomy and prostate cancer: a case-control study in a health maintenance organization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vasectomy and prostate cancer. Chance, bias, or a causal relationship?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Socioeconomic factors and cancer incidence among blacks and whites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Detection and screening for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Occupation, physical activity, and risk of prostate cancer in Shanghai, People's Republic of China

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Physical activity and risk of cancer in the NHANES I population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Physical activity and risk of cancer in middle-aged men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

College athletics, body size, and cancer mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Physical activity and incidence of cancer in diverse populations: a preliminary report.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Occupational physical activity, socioeconomic status, and risks of 15 cancer sites in Turkey

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Lifetime occupational physical activity and incidental prostate cancer (Canada)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Occupational physical activity and risk for prostate cancer in a nationwide cohort study in Sweden

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Physical activity on the job and cancer in Missouri

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Energy restriction in childhood and adolescence and risk of prostate cancer: results from the Netherlands Cohort Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A review of physical activity and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Three limitations of the body mass index

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Body mass and prostatic cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Fatty acids, biliary bile acids, lipid peroxidation products and gallbladder carcinogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Weight and length at birth and risk of early-onset prostate cancer (United States).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Workgroup I: rodent models of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Spontaneous Prostate Adenocarcinomas in Aged Germfree Wistar Rats2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Promotional effects of testosterone and high fat diet on the development of autochthonous prostate cancer in rats.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic intraepithelial neoplasia: animal models 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Autochthonous prostate adenocarcinomas in Lobund-Wistar rats: a model system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Diet and the duration of testosterone-dependent prostate cancer in Lobund-Wistar rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effects of diphosphonate and x-rays on bone lesions induced in rats by prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Enhancement of metastasis of prostate adenocarcinoma cells by immune-suppressive cyclosporine A

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prevention of prostate cancer and liver tumors in L-W rats by moderate dietary restriction.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarinoma-III cells in Lobund-Wistar rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Studies of rhodamine-123: effect on rat prostate cancer and human prostate cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Induction of proliferative lesions of ventral prostate, seminal vesicle, and other accessory sex glands in rats by N-methyl-N-nitrosourea: effect of castration, pretreatment with cyproterone acetate and testosterone propionate and rat strain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Activation of dormant cancer cells in the prostates and seminal vesicles of Lobund-Wistar rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

High incidence and histogenesis of seminal vesicle adenocarcinoma and lower incidence of prostate carcinomas in the Lobund-Wistar prostate cancer rat model using N-nitrosomethylurea and testosterone.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Spontaneous Adenocarcinomas of the Ventral Prostate of Aged A X C Rats 2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Trial to induce prostatic cancer in ACI/Seg rats treated with a combination of 3,2'-dimethyl-4-aminobiphenyl and ethinyl estradiol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Point mutations in the Ki-ras2 gene of codon 12 in the Dunning R-3327 Prostatic Adenocarcinoma system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the dunning rat prostatic carcinoma, R-3327

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

An autocrine motility factor secreted by the Dunning R-3327 rat prostatic adenocarcinoma cell subtype AT2.1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tumorigenesis disrupts hormonal regulation of tenascin expression in regressing Dunning R 3327 H prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of transforming growth factor-beta 1 in prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Change in morphological and functional cytodifferentiation induced by seminal vesicle mesenchyme in cell suspensions of rat Dunning prostatic adenocarcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibition of prostate cancer growth by estramustine and colchicine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mapping of metastasis suppressor gene(s) for rat prostate cancer on the short arm of human chromosome 8 by irradiated microcell-mediated chromosome transfer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Suppression of invasive ability of highly metastatic rat prostate cancer by introduction of human chromosome 8

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Establishment and in vivo characterization of multidrug-resistant dunning R3327 rat prostate-carcinoma cell-lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The development of Casodex (bicalutamide): preclinical studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

High-dose bicalutamide monotherapy for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2'-dimethyl-4-aminobiphenyl (DMAB)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Beef tallow, but not perilla or corn oil, promotion of rat prostate and intestinal carcinogenesis by 3,2'-dimethyl-4-aminobiphenyl

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Carcinogenesis in accessory sex organs of rats induced by 3,2'-dimethyl-4-aminobiphenyl: response to androgen deprivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Establishment and characterization of three androgen-independent, metastatic carcinoma cell lines from 3,2'-dimethyl-4-aminobiphenyl-induced prostatic tumors in F344 rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate-seminal vesicle cancers induced in noble rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Involvement of transforming growth factor alpha (TGFalpha) and epidermal growth factor receptor (EGFR) in sex hormone-induced prostatic dysplasia and the growth of an androgen-independent transplantable carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of combined testosterone and estradiol-17 beta treatment on the metabolism of E2 in the prostate and liver of noble rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The role of Bcl-2 expression in EGF inhibition of TNF-alpha/IFN-gamma-induced villous trophoblast apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Rat estrogen receptor-alpha and -beta, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Adenocarcinomas of the prostate induced by N-nitroso-N-methylurea in rats pretreated with cyproterone acetate and testosterone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Teratogenesis and carcinogenesis in rat offspring after transplacental and transmammary exposure to diethylstilbestrol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Long-term Effects of Perinatal Exposure to Sex Steroids and Diethylstilbestrol on the Reproductive System of Male Mammals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Intravenous vs. intraprostatic administration of N-methyl-N-nitrosourea to induce prostate cancer in rats.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic cancer induced in MRC rats by N-nitrosobis(2-oxopropyl)-amine and N-nitrosobis(2-hydroxypropyl)amine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

High fat diet increases the weight of rat ventral prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The mouse mammary tumor virus long terminal repeat directs expression in epithelial and lymphoid cells of different tissues in transgenic mice.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Bcl-2 accelerates multistep prostate carcinogenesis in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Transgenic models for the study of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Role of transforming growth factor-alpha in human prostate cancer cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Rodent models for targeted oncogenesis of the prostate gland

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Targeting of transgene expression to monocyte/macrophages by the gp91-phox promoter and consequent histiocytic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of androgen on the transcription of rat prostatic binding protein genes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Influence of castration and androgen treatment on the synthesis of prostatic binding protein and the concentration of its mRNA in the rat ventral prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate cancer in a transgenic mouse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A transgenic mouse prostate cancer model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Isolation and characterization of mouse probasin: An androgen-regulated protein specifically expressed in the differentiated prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Impaired prostate tumorigenesis in Egr1-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Pathologic progression of autochthonous prostate cancer in the TRAMP model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Autochthonous mouse models for prostate cancer: past, present and future

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epithelial-mesenchymal interactions in prostatic development. I. morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epithelial-mesenchymal interactions in prostatic development. II. Biochemical observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

p53 protein accumulation and gene mutation in the progression of human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A severe combined immunodeficiency mutation in the mouse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

T cell receptor gene diversity and selection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The biology of the SCID mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Xenografts of primary human prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Survival of human prostate carcinoma, benign hyperplastic prostate tissues, and IL-2-activated lymphocytes in scid mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Development of a high-efficiency method for gene marking of Dunning prostate cancer cell lines with the enzyme beta-galactosidase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Adenovirus-mediated gene transfer in dog prostate: a preclinical study of a relevant model system for gene therapy of human prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The influence of castration on the development of prostatic carcinoma in the dog. 43 cases (1978-1985)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Adenocarcinoma of the canine prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The role of angiostatin in the spontaneous bone and prostate cancers of pet dogs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The SCID mouse mutant: definition, characterization, and potential uses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Workgroup 2: Human xenograft models of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Human primary prostate tumor cell line, ALVA-31: a new model for studying the hormonal regulation of prostate tumor cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen-repressed phenotype in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Ectopic hormone production by a prostatic small cell carcinoma xenograft line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Flow cytometric and karyotypic analysis of a primary small cell carcinoma of the prostate: a xenografted cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Microvascular endothelium of human tumor xenografts expresses mouse (= host) CD31

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Establishment of short-term primary human prostate xenografts for the study of prostate biology and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prognostic value of nuclear morphometry on needle biopsy from patients with prostate cancer: is volume-weighted mean nuclear volume superior to other morphometric parameters?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nuclear changes in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Morphometrically estimated variation in nuclear size. A useful tool in grading prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nuclear roundness factor: a quantitative approach to grading in prostatic carcinoma, reliability of needle biopsy tissue, and the effect of tumor stage on usefulness

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Pathologic aspects of prostate cancer: prediction of malignant potential

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Histologic Grade, DNA Ploidy, and Intraglandular Tumor Extent as Indicators of Tumor Progression of Clinical Stage B Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prognostic criteria in patients with prostate cancer: correlation with volume weighted mean nuclear volume

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Application of confocal scanning laser microscopy for an automated nuclear grading of prostate lesions in three dimensions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nuclear texture analysis: a new prognostic tool in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Entropy-based texture analysis of chromatin structure in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Intratumoral nuclear morphologic heterogeneity in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nucleolar organizer regions and PCNA expression in prostatic cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nucleolar and AgNOR-analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Argyrophilic nucleolar organizer regions in atypical adenomatous hyperplasias, prostatic intraepithelial neoplasias and prostatic neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Argyrophilic nucleolar organizer regions in benign hyperplastic and cancerous human prostates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

High and low risk prostate carcinoma determined by histologic grade and proliferative activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Observations on the number, size and localization of nucleoli in hyperplastic and neoplastic prostatic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Bcl-2 correlates with tumor ploidy and nuclear morphology in early stage prostate carcinoma. A fine needle aspiration biopsy study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Deoxyribonucleic acid cytometric analysis of prostate core biopsy specimens: relationship to serum prostate specific antigen and prostatic acid phosphatase, clinical stage and histopathology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Consensus review of the clinical utility of DNA content cytometry in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

High-grade prostate intraepithelial neoplasia shares cytogenetic alterations with invasive prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Comparison of DNA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: an image cytometric study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

FcR gamma chain deletion results in pleiotrophic effector cell defects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Factors that influence the measurement of prostate cancer DNA ploidy and proliferation in paraffin embedded tissue evaluated by flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Application of low magnification image analysis cytometry to prostatic tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas: clinical research and application.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Flow cytometry as a predictive modality in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Stage B Prostate Cancer: Correlation of DNA Ploidy Analysis With Histological and Clinical Parameters

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Extranodal extension in lymph node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Diagnosis of prostate cancer in needle biopsies after radiation therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

HER2 protein expression and gene amplification in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Experimental studies of apocrine secretion in the dorsal prostate epithelium of the rat

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Three predominant prostatic proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tissue markers in the diagnosis and prognosis of prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate-specific glandular kallikrein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Protection of prostatic acid phosphatase activity in human serum samples by plasmin inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic specific antigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Biochemistry of prostate specific antigen, PSA.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expanded human tissue kallikrein family--a novel panel of cancer biomarkers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tumor-associated urokinase-type plasminogen activator: biological and clinical significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tissue type plasminogen activator as a marker for functional zones, within the human prostate gland

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The urokinase-type plasminogen activator system in prostate cancer metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Matrix metalloproteinases: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Different mRNA and Protein Expression of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitor of Metalloproteinases 1 in Benign and Malignant Prostate Tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Kinetic analysis of androstenedione 5 alpha-reductase in epithelium and stroma of human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of the type 1 and 2 steroid 5 alpha-reductases in human fetal tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Telomerase activity: a biomarker of cell proliferation, not malignant transformation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Detection of telomerase activity in human prostate: a diagnostic marker for prostatic cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of antioxidant enzymes in human prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Localization of antioxidant enzymes and oxidative damage products in normal and malignant prostate epithelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Role of eicosanoids in prostate cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Heat-shock proteins inhibit induction of prostate cancer cell apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The contribution of inhibins and activins to malignant prostate disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of the human relaxin H1 gene in the decidua, trophoblast, and prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical localization of relaxin in human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Animal cell shape changes and gene expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Type IV Procollagen mRNA Regulation: Evidence for Extracellular Matrix/Cytoskeleton/Nuclear Matrix Interactions in Human Urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Role of prostate stem cell antigen in prostate cancer research

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Differential Cytokeratin Expression in Normal, Hyperplastic and Malignant Epithelial Cells From Human Prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Evaluation of a new tumor marker for cytokeratin 8 and 18 fragments in healthy individuals and prostate cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cadherins: a molecular family important in selective cell-cell adhesion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.20408

1 reference

7 January 2021

E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Markers for the development of early prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of E-cadherin in prostate cancer in formalin-fixed, paraffin-embedded tissues: correlation with pathological features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

E-cadherin and beta-catenin are down-regulated in prostatic bone metastases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Single-nucleotide polymorphism in theE-cadherin gene promoter modifies the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

E-, N- and P-cadherin, and alpha-, beta- and gamma-catenin protein expression in normal, hyperplastic and carcinomatous human prostate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Detection and analysis of beta-catenin mutations in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Value of tissue markers p27kip1, MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Determination of prognosis in patients with prostate cancer treated with radical prostatectomy: prognostic value of CD44v6 score

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cell-cell interaction in prostate gene regulation and cytodifferentiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Glucuronosyltransferase activity in human cancer cell line LNCaP.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cancer therapy and prevention by green tea: role of ornithine decarboxylase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical localization of laminin in the basement membranes of normal, hyperplastic, and neoplastic human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Investigation into the mechanism of the loss of laminin 5 (alpha3beta3gamma2) expression in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Detection of the 67-kD laminin receptor in prostate cancer biopsies as a predictor of recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Co-ordinated changes in expression of cell adhesion molecules in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The role of alpha(v)beta(3) in prostate cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Quantification of integrin subunits on human prostatic cell lines--comparison of nontumorigenic and tumorigenic lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cleavage of beta 4 integrin by matrilysin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Changes in collagen metabolism in prostate cancer: a host response that may alter progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tissue sialic acid and fibronectin levels in human prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Neuroendocrine cells in the prostate of the rat, guinea pig, cat, and dog.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Neuroendocrine differentiation in prostatic adenocarcinoma does not represent true Paneth cell differentiation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker"

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Neuroendocrine differentiation in metastatic prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Proliferative activity in benign and neoplastic prostatic epithelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Proliferating cell nuclear antigen in prostatic adenocarcinoma: correlation with established prognostic indicators

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Proliferating cell nuclear antigen/cyclin in incidental carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Proliferative index determination in prostatic carcinoma tissue: is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetics.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part III. Proliferation in normal, injured and diseased tissue, growth factors, differentiation, DNA replication sites and in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Proliferating cell nuclear antigen: more than a clamp for DNA polymerases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the 'Ki-67' proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mitotic activity and prognosis in prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Histological evaluation of prostatic cancer. (II): Reproducibility of a histological grading system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Target to apoptosis: a hopeful weapon for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Caspase-3/CPP32 immunoreactivity and its correlation with frequency of apoptotic bodies in human prostatic carcinomas and benign nodular hyperplasias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Apoptosis and nuclear shapes in benign prostate hyperplasia and prostate adenocarcinoma: comparison with and relation to Gleason score

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The prostatic perineural space and its relation to tumor spread: an ultrastructural study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

BCL-2 in prostate cancer: a minireview

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mechanisms and genes of cellular suicide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Differential expression of apoptosis, Bcl-x and c-Myc in normal and malignant lymphoid tissues.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Signaling inhibitors in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epidermal growth factor receptor biology (IMC-C225).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Production of epidermal growth factor and transforming growth factor-alpha by the androgen-responsive LNCaP human prostate cancer cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Density-dependent regulation of epidermal growth factor receptor expression in DU 145 human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic epidermal growth factor receptors and their regulation by androgens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Anti-EGF receptor therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen receptor and prostate cancer invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

c-erbB-2 oncogene expression in prostatic intraepithelial neoplasia: mounting evidence for a precursor role

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of transforming growth factor beta 1 (TGF beta 1), -beta 2, and- beta 3 by cultured human prostate cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Transforming growth factor beta as a clinical biomarker for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Proprotein convertases regulate activity of prostate epithelial cell differentiation markers and are modulated in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Stromal factors involved in prostate carcinoma metastasis to bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Bone morphogenetic protein-6 expression in normal and malignant prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Bone morphogenetic protein-6: potential mediator of osteoblastic metastases in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibins, activins, and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The role of inhibins and activins in prostate cancer pathogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Regulation of prostate growth by fibroblast growth factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Characteristics of FGF-receptors expressed by stromal and epithelial cells cultured from normal and hyperplastic prostates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Human prostate cancer model: Roles of growth factors and extracellular matrices

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Oncogene amplifications in early-stage human prostate carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Keratinocyte growth factor expression in hormone insensitive prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Human androgen-induced growth factor in prostate and breast cancer cells: its molecular cloning and growth properties

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of fibroblast growth factor-8 in adult rat tissues and human prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Regulation of FGF8 expression by the androgen receptor in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells*

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factor-1 alters apoptotic signalling in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factors and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factors and risk of benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factors and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factor I and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostatic fluid-free insulin-like growth factor-1 in relation to prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Opposing roles for the insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factor-binding protein-3 expression and secretion by cultures of human prostate epithelial cells and stromal fibroblasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Interaction of IGF-binding protein-related protein 1 with a novel protein, neuroendocrine differentiation factor, results in neuroendocrine differentiation of prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

7S nerve growth factor is an insulin-like growth factor-binding protein protease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Autocrine expression of neurotrophins and their receptors in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Rational basis for Trk inhibition therapy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Molecular characterization of the loss of p75(NTR) expression in human prostate tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Loss of low-affinity nerve growth factor receptor during malignant transformation of the human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced cell growth by activation of programmed cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The nerve growth factor receptor gene is at human chromosome region 17q12-17q22, distal to the chromosome 17 breakpoint in acute leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of a Trk high affinity nerve growth factor receptor in the human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of p75(LNGFR) and Trk neurotrophin receptors in normal and neoplastic human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Molecular characterization of the human trk oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Distribution of vascular endothelial growth factor (VEGF) in prostate disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Antitumor effect of reduction of 150-kDa oxygen-regulated protein expression on human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Molecular profiling of angiogenesis markers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Platelet-derived growth factor induces proliferation of hyperplastic human prostatic stromal cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Biomarker expression in prostatic intraepithelial neoplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

c-met proto-oncogene expression in benign and malignant human prostate tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Co-expression of hepatocyte growth factor and its receptor in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Interleukin-6 is an autocrine growth factor in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Adenosine increases interleukin 6 release and decreases tumour necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective de-endothelialization.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Interleukin-6 and prostate cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

TNF-alpha protects dendritic cells from prostate cancer-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Testosterone is a potential augmentor of antioxidant-induced apoptosis in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibition of nuclear factor kappaB induces apoptosis following treatment with tumor necrosis factor alpha and an antioxidant in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

JFC1 is transcriptionally activated by nuclear factor-kappaB and up-regulated by tumour necrosis factor alpha in prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

TNF-mediated cytotoxicity and resistance in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Chromosome abnormalities are associated with unfavorable outcome in prostatic cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Trisomy 7: a potential cytogenetic marker of human prostate cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Linkage of aggressive prostate cancer to chromosome 7q31-33 in German prostate cancer families

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Linkage analysis of prostate cancer susceptibility: confirmation of linkage at 8p22-23

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Gain in chromosome 8q correlates with early progression in hormonal treated prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Allelic loss of chromosomes 16q and 10q in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Comparison of ras activation in prostate carcinoma in Japanese and American men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

ras, p53 and HPV status in benign and malignant prostate tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

International comparison on ras gene mutations in latent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Frequency and characterization of p53 mutations in clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Loss of heterozygosity and overexpression of p53 gene in human primary prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Gene amplifications in advanced-stage human prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Growth factor receptors and oncogene expression in prostate cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Oncogene overexpression and de novo drug-resistance in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Uteroglobin promoter-targeted c-MYC expression in transgenic mice cause hyperplasia of Clara cells and malignant transformation of T-lymphoblasts and tubular epithelial cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Retinoblastoma gene mutations in primary human prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Alterations of the retinoblastoma gene in human prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Molecular markers for predicting prostate cancer stage and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Allelic loss on chromosomes 8p, 22q and 18q (DCC) in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Allelic loss and microsatellite instability in prostate cancers in Japan.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

nm23-H4, a new member of the family of human nm23/nucleoside diphosphate kinase genes localised on chromosome 16p13

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Association of nm23 protein levels in human prostates with proliferating cell nuclear antigen expression at autopsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Quantitation of NM23 expression in human prostate tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Increased levels of nm23 H1/nucleoside diphosphate kinase A mRNA associated with adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of KAI1 in paraffin-embedded normal, hyperplastic and neoplastic prostate and prostate carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

KAI1/CD82 protein expression in primary prostate cancer and in BPH associated with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

KAI1 expression can be a predictor of stage A prostate cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical expression of pi-class glutathione S-transferase is down-regulated in adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

DNA-based detection of prostate cancer in urine after prostatic massage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Glutathione S-transferase GSTP1 genotypes are associated with response to androgen ablation therapy in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen-regulated gene expression in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen receptor mutations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The human androgen receptor: structure/function relationship in normal and pathological situations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen-selective gene regulation in the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen receptors in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Molecular biology of the androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The role of the androgen receptor in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen-receptor gene structure and function in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The CAG trinucleotide repeat length in the androgen receptor does not predict the early onset of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen receptor CAG polymorphism and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Expression and somatic mutation on androgen receptor gene in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Establishment and characterization of monoclonal antibody against androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical localization of androgen receptors with mono- and polyclonal antibodies to androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Antipeptide antibodies to two distinct regions of the androgen receptor localize the receptor protein to the nuclei of target cells in the rat and human prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen receptor expression in prostatic intraepithelial neoplasia and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Human androgen receptor expression in prostate cancer following androgen ablation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen receptors in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A genetic sequence change in the 3'-noncoding region of the androgen receptor gene in prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Genetic alterations of androgen receptor gene in Japanese human prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen receptor CAG repeats and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African-American population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Transmission/disequilibrium tests of androgen receptor and glutathione S-transferase pi variants in prostate cancer families

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The CAG repeat within the androgen receptor gene and its relationship to prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Delineation of prognostic biomarkers in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

The polycomb group protein EZH2 is involved in progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

High expression of the Met receptor in prostate cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Caspase- and serine protease-dependent apoptosis by the death domain of FADD in normal epithelial cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Osteocalcin gene HindIII C/T polymorphism is a biomarker for prostate cancer and responsiveness to hormone therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Translational infidelity and human cancer: role of the PTI-1 oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Influence of Age and Endocrine Factors on the Volume of Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Changes in the Metabolism of Dihydrotestosterone in the Hyperplastic Human Prostate*

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Influence of pertussis toxine on local progression and metastasis after orthotopic implantation of the human prostate cancer cell line PC3 in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

An in vivo model of prostate carcinoma growth and invasion in bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Influence of linomide on local tumor growth and metastasis of the human hormone-resistant prostate cancer cell line PC3 in an orthotopic model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Black tea polyphenols inhibit IGF-I-induced signaling through Akt in normal prostate epithelial cells and Du145 prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Effect of flavonoids on cell cycle progression in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Tumor-specific and photodependent cytotoxicity of hypericin in the human LNCaP prostate tumor model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dibenzoylmethane induces cell cycle deregulation in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

ErbB kinases and NDF signaling in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Spontaneous metastasis of PC-3 cells in athymic mice after implantation in orthotopic or ectopic microenvironments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Canine prostate induces new bone formation in mouse calvaria: A model of osteoinduction by prostate tissue.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Identification by C-banding of two human prostate tumour cell lines, 1013L and DU 145

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Site-specific growth of the prostate xenograft line UCRU-PR-2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Characterization of ALVA-41 cells, a new human prostatic cancer cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Metastasis-associated alterations in phospholipids and fatty acids of human prostatic adenocarcinoma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Establishment of new human prostatic cancer cell line (JCA-1).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Establishment of a new prostatic carcinoma cell line (TSU-Pr1).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A proliferative effect of transforming growth factor-beta1 on a human prostate cancer cell line, TSU-Pr1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Isolation and characterization of a novel human prostatic stromal cell culture: DuK50.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Isolation of a human prostate carcinoma cell line (DU 145)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

A novel human cancer culture model for the study of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

In vitro characterization of MAT LyLu: a Dunning rat prostate adenocarcinoma tumor subline

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Isolation and partial characterization of an epithelial cell line (RPE-F344) from the regenerating prostate of a normal adult male rat.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Development of two cloned epithelial cell lines from normal adult mouse and rat ventral prostates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Dietary beta-carotene, vitamin C, and risk of prostate cancer: results from the Western Electric Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20408

7 January 2021

Identifiers

DOI

10.1002/CNCR.20408

1 reference

release_7wkwfkwoczhl3pud7ouxd3bkp4

1 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7wkwfkwoczhl3pud7ouxd3bkp4

24 November 2022

mapped directly with Wikidata item

1 reference